Easterly Government Properties, Inc. (DEA) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with growth in Core FFO and reduced cash leverage. The development pipeline is progressing well, and the company maintains a stable liquidity position. Despite some delays in project completion, management's strategic focus on disciplined capital allocation and leveraging partnerships is positive. The reaffirmed investment-grade rating and steady shareholder return plan further support a positive outlook. Market cap suggests moderate reaction potential, hence a positive sentiment with a likely stock price increase of 2% to 8%.
Key Financial Performance
Core FFO growth 3% year-over-year growth from 2024 to the midpoint of 2025 guidance range, driven by growth from acquisitions, strong renewal execution, and prudent portfolio management.
Portfolio occupancy Remains near historical highs at 97%, reflecting the durability of tenancy and mission-critical focus.
Weighted average lease term (WALT) Approximately 10 years, highlighting the strength and stability of the portfolio.
Cash available for distribution $29.3 million, reflecting steady operational performance.
Cash leverage Reduced from 7.9x to 7.6x during the quarter, aided by a $102 million progress payment for the FDA Atlanta project.
Net income per share $0.03 on a fully diluted basis.
Core FFO per share Grew to $0.76, slightly above expectations.
Development pipeline progress Includes breaking ground on the state Crime Lab in Fort Myers, Florida, and nearing completion of the FDA Atlanta project, which is expected to commence leasing in December 2025.
Debt capital Recast and upsized the 2018 senior unsecured term loan from $174.5 million to $200 million, with an added accordion feature. KBRA reaffirmed investment-grade rating with a stable outlook.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Development of FDA Atlanta: The largest development project in the company's history, nearing completion with lease commencement expected in December 2025.
State Crime Lab in Fort Myers, Florida: Construction began in August 2025, with delivery expected in Q4 2026.
Acquisition of York Space Systems headquarters: Positions the company towards a 15% government-adjacent exposure, reflecting demand for specialized facilities supporting U.S. Defense and Space partners.
Portfolio Occupancy: Maintained near historical highs at 97% with a weighted average lease term of approximately 10 years.
Lease Renewals: Successfully extended leases at USCIS Lincoln and VA - Golden, with progress on 2025 and 2026 renewals.
Core FFO Growth: Achieved 3% growth from 2024 to the midpoint of 2025 guidance, driven by acquisitions, renewals, and portfolio management.
Leverage Optimization: Targeting a medium-term cash leverage goal of 6x, down from historical levels of 7-8x, to enhance investor comparability and reduce capital costs.
Expansion into State and Local Tenancy: Diversifying portfolio to include state and local government leases, which can extend up to 40 years, increasing weighted average lease term.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Federal Government Shutdown: The federal government remains partially closed, which could potentially disrupt operations. However, the company believes the government will not default on leases.
Leverage Optimization: The company is targeting a medium-term cash leverage goal of 6x, down from historical levels of 7-8x. High leverage levels could impact comparability with REIT peers and increase capital costs.
Cost of Capital: Efforts to improve cost of capital, including debt and equity, are ongoing. Failure to optimize could hinder growth and acquisition opportunities.
Development Pipeline Risks: Delays or issues in the development pipeline, such as the FDA Atlanta project, could impact financial performance and growth objectives.
Economic and Policy Backdrop: While the company aims to build a portfolio resilient to economic and policy changes, adverse conditions could still impact operations.
Tenant Retention and Renewals: Challenges in renewing leases or retaining tenants could affect occupancy rates and financial stability.
Debt Capital Access: The company is working to secure additional investment-grade ratings to access public bond markets. Limited access to debt capital could constrain growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Core FFO Growth: Easterly is targeting 2% to 3% annual core FFO growth. For 2025, the guidance range is $2.98 to $3.02 per share, reflecting 3% growth over 2024. For 2026, the guidance range is $3.05 to $3.12 per share, supported by operational efficiencies, portfolio expansion, and development project completions.
Development Pipeline: The company expects to deliver the FDA Atlanta project in December 2025, which will reduce cash leverage below 7.5x. The state Crime Lab in Fort Myers, Florida, is on track for a Q4 2026 delivery. The company anticipates $50 million to $100 million in gross development-related investment in 2026.
Acquisitions: Easterly plans to execute $50 million in wholly-owned acquisitions in 2026, with potential to reach $400 million, leveraging a $1.5 billion pipeline. The company aims to achieve spreads above its cost of capital.
Leverage Optimization: The company is targeting a medium-term cash leverage goal of 6x, down from historical levels of 7-8x. Progress has been made, with cash leverage reduced to 7.6x in Q3 2025 and expected to further decline upon project completions.
Capital Management: Easterly is focused on improving its cost of capital through leverage optimization and securing additional investment-grade ratings. The company successfully recast and upsized its senior unsecured term loan and added an accordion feature.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the reason for the delay in the Flagstaff warehouse completion?
A:The government is still working on the design of the courthouse, balancing 3 or 4 agencies in the building that collaborate on the space design. The lump sum and TI project are expected to finalize in 2026, which naturally pushes the ultimate delivery date.
Q:What are the company's thoughts on capital allocation and alternative funding sources for development?
A:The company evaluates cost of equity through FFO cost of equity and weighted average cost of capital, which is in the high 9% range. They believe they can develop at 100 basis points to the upper end of the FFO range due to their expertise. They also have strong relationships with sovereign wealth funds and other partners, which could provide more attractive funding options during interim periods.
Q:Why is the $50 million acquisition guidance for 2026 lower than usual?
A:The lower guidance reflects the company's focus on achieving 2% to 3% growth while managing cost of capital challenges. The $50 million target is a low bar to ensure growth expectations are met, and the company has a strong pipeline of $1.5 billion to support this target.
Q:Will dispositions be part of the strategy to reduce leverage, and how will this impact development starts?
A:Dispositions are unlikely to significantly reduce leverage without a decrease in interest rates. The company aims to align leverage with peers and may use external partners and JVs to support development while managing leverage.
Q:Does the government shutdown lead to delays or threats to agencies?
A:The shutdown slows things down but does not diminish the portfolio's value. There is no threat to agencies, and the company continues to work with the government during the shutdown. Agencies remain enthusiastic about their missions.
Q:What are the company's strategies to achieve 6x cash flow leverage?
A:The company plans to leverage attractive development projects, structure financials to achieve a cost of capital 100 basis points above market rates, and use a robust pipeline to deleverage over the next 24 to 36 months. Joint ventures are a less important but possible avenue.
Q:What is the company's target mix of federal, state, and local government exposure?
A:The target mix is 70% federal, 15% state and local, and 15% adjacent spaces. The company aims to grow state and local and adjacent exposure while continuing to acquire high-credit mission-critical U.S. government properties.
Q:What is the company's approach to modernizing lease structures with the GSA?
A:The GSA is open to modernizing lease structures, including embedding lease escalators. The company has successfully included escalators in recent renewals, reflecting the GSA's evolving leasing practices.
Q:Why has the company shifted focus from 4% growth to 2%-3% growth with lower leverage?
A:The shift aims to align with market expectations and improve cost of capital. The company believes lower leverage will address investor concerns and support long-term growth.
Q:What are the headwinds for 2026 guidance, and are there any planned dispositions?
A:The $0.08 increase in 2026 guidance is driven by FDA Atlanta and same-store growth, offset by increased G&A expenses. There are no planned dispositions for 2026.
Q:How does the company view the impact of government shutdowns on lease payments?
A:The company is confident in receiving lease payments during shutdowns, as leases are funded for 6 months or more. Non-payment would constitute a default by the U.S. government, which is highly unlikely.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific cap rates for potential asset sales and provided limited details on how exactly they plan to achieve the 6x leverage target beyond general strategies. Additionally, while they discussed the impact of government shutdowns, they did not provide specific examples of how delays might affect ongoing projects.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Colorado goal
Darrell Crate
Defense Space
Easterly ability
Easterly mission
Easterly portfolio
Easterly trust
FFO midpoint
FFO store
Immigration facility
Kabuki theater
Officer conference
Space Systems
Space partner
Systems headquarters
York Space
ability compounding
access path
acquisition York
acquisition cost
acquisition pipeline
acquisition renewal
action core
administration cycle
age durability
agency Easterly
agency balance
alignment return
approach action
approach capital
cash leverage
comparability
demand
history
lease term
nation
portfolio occupancy
priority
progress
shutdown
way
DEA Transcript
Easterly Government Properties, Inc. (DEA) Q1 2026 Earnings Call Transcript
Unknown4-27
The earnings call summary lacked detailed information on financial performance, strategic initiatives, and operational updates, leading to uncertainty. The absence of specific figures for key financial metrics and lack of discussion on returns or strategic outlook contributes to a negative sentiment. Additionally, the acknowledgment of potential risks without clear guidance adds to investor concerns.
Easterly Government Properties, Inc. (DEA) Presents at Citi's Miami Global Property CEO Conference 2026 Transcript
Neutral3-2
Easterly Government Properties, Inc. (DEA) Q4 2025 Earnings Call Transcript
Positive2-23
The earnings call reveals a stable financial performance with a 6% YoY growth in Core FFO and high occupancy rates. The Q&A indicates optimism about the $1.5 billion pipeline and government efficiency, despite some management ambiguity. The completion of the FDA Atlanta facility and strong acquisition terms in Virginia are positive signs. While economic uncertainties and strategic risks exist, the company's focus on efficiency and partnerships suggests a positive outlook. Given the market cap, a 2%-8% positive stock movement is expected.
Easterly Government Properties, Inc. (DEA) Q3 2025 Earnings Call Transcript
Positive10-27
The earnings call highlights strong financial performance with growth in Core FFO and reduced cash leverage. The development pipeline is progressing well, and the company maintains a stable liquidity position. Despite some delays in project completion, management's strategic focus on disciplined capital allocation and leveraging partnerships is positive. The reaffirmed investment-grade rating and steady shareholder return plan further support a positive outlook. Market cap suggests moderate reaction potential, hence a positive sentiment with a likely stock price increase of 2% to 8%.
DEA Slides
DEA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
